hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06276894, orgStudyIdInfo id: IRB #2064530-1, briefTitle: Functional Near-Infrared Spectroscopy (fNIRS) Assessing Neural Activity During Virtual Reality Walking Intervention, acronym: fNIRS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Craig Hospital, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the safety and feasibility of using a portable neuroimaging device called functional near-infrared spectroscopy (fNIRS) to successfully analyze fNIRS data in individuals with chronic TBI during treadmill training augmented with VR., conditionsModule conditions: Traumatic Brain Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Motek C-Mill™ treadmill, interventions name: training session with and without VR wearing the fNIRS cap, outcomesModule primaryOutcomes measure: Incidence of Treatment-Related Adverse Events (e.g., Safety and Tolerability), primaryOutcomes measure: Acceptability of the intervention, primaryOutcomes measure: fNIRS Data Quality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Craig Hospital, city: Englewood, state: Colorado, zip: 80113, country: United States, geoPoint lat: 39.64777, lon: -104.98776, hasResults: False
protocolSection identificationModule nctId: NCT06276881, orgStudyIdInfo id: DSC1001, secondaryIdInfos id: 1R43DA054845-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1R43DA054845-01, briefTitle: Visual Stimulation for Pain Relief, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-03, primaryCompletionDateStruct date: 2022-12-28, completionDateStruct date: 2023-05-01, studyFirstPostDateStruct date: 2024-02-26, resultsFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Dandelion Science, class: INDUSTRY, collaborators name: National Institutes of Health (NIH), collaborators name: National Institute on Drug Abuse (NIDA), descriptionModule briefSummary: The goal of this study is to investigate a novel neuromodulatory approach utilizing visual stimulation to impact pain perception in healthy participants., conditionsModule conditions: Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 75, type: ACTUAL, armsInterventionsModule interventions name: Visual Stimulation, outcomesModule primaryOutcomes measure: Visual Analog Scale (VAS) Score, primaryOutcomes measure: Event-related Potential (ERP), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Dandelion Science, city: Hoboken, state: New Jersey, zip: 07030, country: United States, geoPoint lat: 40.74399, lon: -74.03236, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2021-12-21, uploadDate: 2024-03-08T12:20, filename: Prot_SAP_000.pdf, size: 689133, hasResults: True
protocolSection identificationModule nctId: NCT06276868, orgStudyIdInfo id: HELEN-017, briefTitle: Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2029-06-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Henan Cancer Hospital, class: OTHER_GOV, descriptionModule briefSummary: This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before surgery. It is intended to further explore the efficacy and safety of the new adjuvant treatment for TPBC patients with step-down therapy., conditionsModule conditions: Breast Cancer, conditions: HER2-positive Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective, single arm clinical study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: Dalcilib+letrozole+HP treatment group, outcomesModule primaryOutcomes measure: pathologic complete response, secondaryOutcomes measure: Adverse event occurrence, secondaryOutcomes measure: objective response rate, secondaryOutcomes measure: Residual cancer burden, secondaryOutcomes measure: Event free survival, secondaryOutcomes measure: Disease free survival, secondaryOutcomes measure: Distant disease/recurrence free survival, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Henan cacer hospital, city: Henan, state: Henan, zip: 450008, country: China, hasResults: False
protocolSection identificationModule nctId: NCT06276855, orgStudyIdInfo id: CUtülay, briefTitle: Sleep Hygiene Education in Individuals With Fibromyalgia; Sleep Quality, Pain and Depression, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-06-23, primaryCompletionDateStruct date: 2021-07-01, completionDateStruct date: 2021-12-31, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Cumhuriyet University, class: OTHER, descriptionModule briefSummary: Objective: This semi-experimental study was conducted to determine the effect of sleep hygiene education on sleep quality, pain, and depression in individuals with fibromyalgia.Patients and methods: A sample of 70 individuals with fibromyalgia (35 experimental, 35 control) were included in the study. Data was collected using the Pittsburgh Sleep Quality Index, the Visual Analog Scale, and the Beck Depression Inventory., conditionsModule conditions: Fibromyalgia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Experimental group Control group, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: Sleep hygiene education, outcomesModule primaryOutcomes measure: Demographic Information Form (DIF)., primaryOutcomes measure: Pittsburgh Sleep Quality Index (PSQI)., primaryOutcomes measure: Visual Analog Scale (VAS)., primaryOutcomes measure: Beck Depression Inventory (BDI)., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sivas Cumhuriyet University, city: Sivas, state: Center, zip: 58140, country: Turkey, geoPoint lat: 39.74833, lon: 37.01611, hasResults: False
protocolSection identificationModule nctId: NCT06276842, orgStudyIdInfo id: 12345678, briefTitle: Efficacy of Combining an Inferior Alveolar Nerve Block With a Buccal Infiltration, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-04-01, primaryCompletionDateStruct date: 2020-09-30, completionDateStruct date: 2020-09-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: CIMS Dental College, class: OTHER, descriptionModule briefSummary: OBJECTIVE To compare the effectiveness of using both a combined technique of an Inferior Alveolar Nerve block and buccal infiltration with that achieved by utilizing an Inferior Alveolar Nerve block alone for endodontic treatment of mandibular molars with irreversible pulpitis.STUDY DESIGN Randomized clinical trial PLACE AND DURATION OF STUDY Operative Dentistry Department of Armed Forces Institute of Dentistry Rawalpindi, from 1st April 2020 to 31st September 2020.MATERIAL AND METHODS A total of 120 patients were enrolled in the study. Sixty patients of group A received conventional Inferior Alveolar Nerve block and sixty patients of Group B received buccal infiltration along with conventional Inferior Alveolar Nerve block., conditionsModule conditions: Pulpitis, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ACTUAL, armsInterventionsModule interventions name: Inferior Alveolar Nerve Block, interventions name: Buccal Infiltration, interventions name: Inferior Alveolar Nerve Block and Buccal Infiltration, outcomesModule primaryOutcomes measure: Comparison of Anesthesia Effectiveness Between Combined Technique (Inferior Alveolar Nerve Block and Buccal Infiltration) and Inferior Alveolar Nerve Block Alone, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Dr Ayesha Ahmed, city: Multan, country: Pakistan, geoPoint lat: 30.19679, lon: 71.47824, hasResults: False
protocolSection identificationModule nctId: NCT06276829, orgStudyIdInfo id: 02.05.2023/291, briefTitle: Behçet and LDH/Albumin, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-02-01, primaryCompletionDateStruct date: 2023-04-01, completionDateStruct date: 2023-04-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Ataturk University, class: OTHER, descriptionModule briefSummary: ABSTRACT Objective: To investigate whether the lactate dehydrogenase to albumin ratio can be used as a parameter to determine disease severity in Behçet's disease, an inflammatory disease, by comparing it to healthy controls.Patients and Methods: In this retrospective cohort study, patients with Behçet's disease aged 18-69 years who presented to the outpatient clinic between February 2020 and April 2023 and healthy individuals of similar age and gender were enrolled. LDH, albumin levels, and LDH/albumin ratio of both groups were compared. Clinical findings and characteristics of Behçet's patients and disease severity were recorded and analyzed in relation to LDH/albumin ratio., conditionsModule conditions: Behcet's Disease, conditions: Albumin, conditions: Lactate Dehydrogenase, conditions: Disease Severity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 1, type: ACTUAL, armsInterventionsModule interventions name: LDH/albumin ratio, outcomesModule primaryOutcomes measure: LDH/albumin ratio, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 69 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erdal Pala, city: Erzurum, zip: 25240, country: Turkey, geoPoint lat: 39.90861, lon: 41.27694, hasResults: False
protocolSection identificationModule nctId: NCT06276816, orgStudyIdInfo id: 2022-LC14, briefTitle: Cardiac Denervation Ablation Strategy for Severe Sinus Bradycardia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-13, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: China National Center for Cardiovascular Diseases, class: OTHER_GOV, descriptionModule briefSummary: This is a prospective clinical observation and registration study. The investigator aimed to evaluate the efficacy and safety of cardiac denervation ablation as a treatment strategy for severe sinus bradycardia., conditionsModule conditions: Sinus Bradycardia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 88, type: ESTIMATED, outcomesModule primaryOutcomes measure: Number of patients with postoperative recurrence of bradycardia symptoms, secondaryOutcomes measure: The result of the atropine test, secondaryOutcomes measure: Changes in quality of life measured by Medical Outcomes Study 36- Item Short Form Health Survey (SF-36), secondaryOutcomes measure: Changes in quality of life measured by EuroQol Five Dimensions Questionnaire Visual Analogue Scale (EQ VAS), secondaryOutcomes measure: Changes in minmum heart rate, secondaryOutcomes measure: Changes in mean heart rate, secondaryOutcomes measure: Changes in deceleration capacity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: 1Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, status: RECRUITING, city: Beijing, country: China, contacts name: Yao Yan, MD PhD, role: CONTACT, phone: +86-1390-1121-319, email: ianyao@263.net.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06276803, orgStudyIdInfo id: Adenocyte 104, briefTitle: The LINFU® U.S. Registry for the in the General Population Without Risk Factors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2034-04-15, completionDateStruct date: 2034-06-15, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Adenocyte, LLC, class: INDUSTRY, descriptionModule briefSummary: Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.. In this study, LINFU® will be evaluated in the general population with no risk factors and who exhibit no signs or symptoms of disease, This study will help determine if LINFU® can be used to help identify early, asymptomatic pancreatic ductal adenocarcinoma (PDAC) or their precursor lesions (PanIn-2, PanIn-3)., conditionsModule conditions: Pancreatic Cancer, conditions: Pancreatic Ductal Adenocarcinoma, conditions: Pancreatic Dysplasia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: LINFU®, outcomesModule primaryOutcomes measure: The number of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU®, primaryOutcomes measure: The change in size of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® will be determined long term, secondaryOutcomes measure: Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified with LINFU® that require medical or surgical intervention, otherOutcomes measure: Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified with LINFU®, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06276790, orgStudyIdInfo id: ChengdeCentralHospital, briefTitle: Objective Analysis of Caesarean Scar Pregnancy, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-01-18, primaryCompletionDateStruct date: 2022-12-23, completionDateStruct date: 2022-12-25, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Chengde Central Hospital, class: OTHER_GOV, descriptionModule briefSummary: This study uses a systematic scoring method combined with clinical and ultrasound data to comprehensively evaluate patient conditions and explore the guiding value of the ultrasound quantitative scoring system for selecting the surgical approach for caesarean scar pregnancy., conditionsModule conditions: Caesarean Scar Pregnancy, conditions: Ultrasound Scoring System, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 117, type: ACTUAL, armsInterventionsModule interventions name: ultrasound-guided/hysteroscopic curettage, interventions name: Procedure/Surgery: laparoscopic removal of the pregnancy lesion, outcomesModule primaryOutcomes measure: intraoperative blood loss, primaryOutcomes measure: length of hospital stay, primaryOutcomes measure: serum β-HCG levels, eligibilityModule sex: FEMALE, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chengde Central Hospital, city: Chengde, zip: 067000, country: China, geoPoint lat: 40.9519, lon: 117.95883, hasResults: False
protocolSection identificationModule nctId: NCT06276777, orgStudyIdInfo id: SPRG Dentin Hypersensitivity, briefTitle: The Effect of Using Desensitizers Containing S-PRG In Treatment Of Dentin Hypersensitivity Over 6 Months: A Randomized Clinical Trial, acronym: S-PRG, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-11-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Eman Omar Elfarouk, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the effect of desensitizer containing S-PRG have similar effect as sodium fluoride with functionalized tri-calcium phosphate containing desensitizer in relieving dentinal hypersensitivity in adult patients for six months follow-up. patients will be asked to report pain degree on the visual analogue scale (VAS) along the follow up periods on both groups., conditionsModule conditions: Dentin Hypersensitivity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Participants and both assessors will be blind to the type of material used., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Tooth varnish (PRG Barrier Coat from Shofu), interventions name: Tooth varnish (Clinpro white varnish 3M), outcomesModule primaryOutcomes measure: Dentin hypersensitivity reduction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Dentistry Cairo University, city: Cairo, zip: 11331, country: Egypt, contacts name: Eman Omar, bachelor, role: CONTACT, phone: 01156677558, email: eman.omar@dentistry.cu.edu.eg, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06276764, orgStudyIdInfo id: Adenocyte 103, briefTitle: The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2034-03-30, completionDateStruct date: 2034-05-01, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Adenocyte, LLC, class: INDUSTRY, descriptionModule briefSummary: In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia). The study will also help determine if LINFU® results in earlier intervention, treatment and improvement in patient outcomes., conditionsModule conditions: IPMN, Pancreatic, conditions: Pancreas Cancer, conditions: Pancreatic Cyst, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 500, type: ESTIMATED, armsInterventionsModule interventions name: LINFU®, interventions name: Standard imaging tests, outcomesModule primaryOutcomes measure: The number of pancreatic ductal adenocarcinomas or their precursor lesions, dysplasia, identified only with LINFU® will be compared to standard screening methods, secondaryOutcomes measure: The change in size of pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® will be determined over a 5 year period, secondaryOutcomes measure: Determine the number of patients with early pancreatic ductal adenocarcinomas and their noninvasive precursor lesions identified only with LINFU® that require medical or surgical intervention., otherOutcomes measure: Yearly survival rate of patients with early pancreatic ductal adenocarcinomas or their noninvasive precursor lesions identified only with LINFU®, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06276751, orgStudyIdInfo id: E1-23-3870 ptx endtidalco2, briefTitle: The Diagnostic Value of End-Tidal CO2 in Patients Diagnosed With Pneumothorax, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-15, primaryCompletionDateStruct date: 2024-02-06, completionDateStruct date: 2024-02-13, studyFirstPostDateStruct date: 2024-02-26, lastUpdatePostDateStruct date: 2024-02-26, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: Pneumothorax (PTX) is defined as the accumulation of air in the pleural space. PTX can cause a disruption in the perfusion of lung tissue in the affected area and increase intrathoracic pressure, potentially leading to obstruction of venous return and, consequently, posing a life-threatening condition. Therefore, PTX requiring urgent intervention is a significant concern in emergency departments.End-tidal carbon dioxide (ETCO2) provides insight into carbon dioxide levels resulting from lung perfusion and serves as a respiratory parameter informing the prognosis of various critical illnesses. One of the most important factors determining lung perfusion is the effective lung area. Among the crucial issues for emergency departments are PTX cases, which typically regress following urgent intervention, leading to the establishment of an effective lung area. Hypotheses have been proposed in the literature suggesting that ETCO2 may be affected in PTX cases due to the relationship between effective lung area and ETCO2.In this study, investigetors aimed to investigate changes in ETCO2 levels following tube thoracostomy applied to PTX cases., conditionsModule conditions: Pneumothorax, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 43, type: ACTUAL, armsInterventionsModule interventions name: End-tidal CO2 monitor, outcomesModule primaryOutcomes measure: ETCO2-0, primaryOutcomes measure: ΔETCO2-1, primaryOutcomes measure: ΔETCO2-2, primaryOutcomes measure: ETCO2-1, primaryOutcomes measure: ETCO2-2, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara Bilkent Şehir Hastanesi, city: Ankara, state: Çankaya, zip: 06170, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False